FGP
SUPN icon

Freestone Grove Partners’s Supernus Pharmaceuticals SUPN Stock Holding History

Freestone Grove Partners’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.7M Sell
316,398
-324,921
-51% -$15.6M 0.09% 246
2026
Q1 		$33.1M Buy
641,319
+445,001
+227% +$22.7M 0.23% 147
2025
Q4 		$9.76M Buy
+196,318
New +$9.55M 0.07% 294

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Freestone Grove Partners's SUPN Position: Q2 2026 in Review

Freestone Grove Partners reduced its Supernus Pharmaceuticals (SUPN) stake by 51% in Q2 2026, selling an estimated $15.6M and leaving 316,398 shares worth $14.7M. The position accounts for 0.09% of the portfolio, ranked #246.

Freestone Grove Partners first reported a position in SUPN in Q4 2025 and has held it in 3 quarters since. The position peaked at $33.1M in Q1 2026. 334 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Freestone Grove Partners held 316,398 shares of Supernus Pharmaceuticals worth $14.7M as of Q2 2026.
  • Freestone Grove Partners sold 324,921 Supernus Pharmaceuticals shares in Q2 2026, an estimated $15.6M.
  • Supernus Pharmaceuticals made up 0.09% of Freestone Grove Partners's portfolio in Q2 2026, its #246 holding.
  • Freestone Grove Partners first reported a position in Supernus Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Freestone Grove Partners's Supernus Pharmaceuticals position peaked at $33.1M in Q1 2026.
  • 334 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.